

## Malignant bone tumors

### Incidence

Myeloma	45%
Osteosarcoma	24%
Chondrosarcoma	12%
Lymphoma	8%
Ewing's Sarcoma	7%

Commonest primary bone sarcoma is osteosarcoma

### X ray Questions to ask

1. Solitary or Multiple
2. What type of bone involved?
3. Which part of the bone: Epiphyseal , Metaphyseal or Diaphyseal
4. Margins: Well defined/ill defined  
Geographic Benign  
Malignant: Moth eaten  
Permeative
5. Periosteal reaction
6. Any calcification in the lesion

Geographic

Permeative

Moth Eaten



## **Zone of transition**

It is the most reliable indicator to differentiate benign from malignant lesion

The zone of transition is the border between the lesion and the normal bone

Benign lesions are well defined [narrow zone of transition = fine line or sclerosed]

In malignant lesions there is ill defined [Wide zone of transition].

Zone of transition is applied to lytic lesion only

**Beware:** Eosinophilic granuloma

Infection

Osteoid Osteoma

Stress fractures

These benign lesion may have radiological appearance of malignancy

## **CT, MRI & BONE scan Assessment is essential**

**CT** Bone involvement better seen [eg Osteoid osteoma]

Difficult areas: Pelvis and spine and scapula

Pulmonary metastasis

**MRI** It is a gold standard

Defines soft tissue involvement well seen

Skip lesion

Marrow spread

Activity of the tumor [Gadolinium]

Neurovascular relation

T1 good for anatomy and T2 for pathology

Gadolinium: Only rim enhancement means benign cyst

## Enneking Staging of bone sarcomas


Stage I: Low grade sarcomas

Stage II: High grade sarcomas

Stage III: High grade + Metastasis

(A: Intracompartment

B: Extracompartment)



## SURGICAL MARGINS

RADICAL RESECTION

WIDE EN BLOC

MARGINAL

INTRACAPSULAR

## Osteosarcoma

1970's 20% 5 yrs survival; Present 80% 5 yr survival.

Increased frequency: with Li Fraumeni Syndrome  
TP 53 deficiency  
Retinoblastoma

Age: I Peak is in the II decade [75%]; II peak is after 60 yrs

Sex : Male: Female = 1.5: 1

Common sites : Around knee 50%  
Proximal shoulder


### Biochemistry

Elevated alkaline phosphatase 50% patients  
Recently LDH: Prognostic

- I Classic osteosarcoma
  - Chondroblastic
  - Osteoblastic
  - Osteoblastic

- II The surface [Juxtacortical]
  - Parosteal,
  - Periosteal,
  - High-grade surface tumors.

- III Secondary osteosarcomas:
  - Paget disease
  - Post-irradiation sarcomas,
  - Fibrous dysplasia and bone infarcts.



## X ray

Wider zone of transition

Permeative or Moth eaten

Destruction of the cortex

Sclerosis or lysis or mixed

Codmans triangle

Sunburst appearance

Parosteal: Distal femur; Pasted on

Appearance of Parosteal, Periosteal and  
Telangectatic



Presence of secondaries in the lungs [15% Survival Vs 80% survival at one year]

Paget's osteosarcoma has worse prognosis.

## Treatment

1. Discuss with tumor centre and biopsy

2. Principle of management:

Surgical: Amputation Vs Limb preservation.

Mortality rate is similar and presently limb preservation

Limb preservation: I biopsy

Chemotherapy

Chemotherapy: <90% necrosis +ve cells

En bloc excision of the tumor

Part is replaced by artificial joint or allograft

Continue Chemotherapy

Observation for recurrence

Patient with secondaries in the lungs: May need excision of secondaries

**MACI** Methotrexate, Adriamycin, Cisplatin, and Ifosfamide [MACI].

are commonly used. Also doxorubicin is used

## Prognosis

Recent report based on 560 cases of Osteosarcoma

Patients with inadequate surgical margin, should undergo immediate amputation especially with poor chemotherapy response

Currently: long term survival is 60 to 80% in non-metastatic tumor

Those with metastases: 10-20% at 5 yr

## Parosteal Osteosarcoma

4% all Osteosarcoma

Common in females over 20 years

Best prognosis [94% survival]

75% distal posterior femur.

Rest : Proximal humerus and tibia.



## **X ray**

Lobulated sclerotic mass

No involvement of medullary canal usually

Pasted on appearance

## **Treatment**

Wide excision

No chemotherapy is required

## **Chondrosarcoma**

Most common sarcoma of bone in patients over 40 years

II common bone sarcoma [after Osteosarcoma ]

It represents about 25% of all bone sarcoma

Typically occurs in 40 and 60 years.

### Types

Primary

Secondary chondrosarcoma : <1% of Osteochondroma

1-2 multiple exostosis

50% with Olliers and Maffucci's Enchondroma

These secondary sarcomas are almost always histologically low-grade

Site: Pelvis is the commonest site

Femur, Humerus, scapula, ribs

Painful enchondroma in a long bone:

Suspect malignancy

## **X ray**

Botchy calcification

Pop corn appearance

Cortical involvement destruction

Soft-tissue extension.

Periosteal reaction



CT: Investigation of choice

MRI: For soft-tissue extension

and Relation to neurovascular bundle.

Medullary fill greater than 90% is predictive of chondrosarcoma.

Open biopsy preferred. Biopsy specimens should be taken from the areas of most concern.

A major drawback is sampling error due to tumor heterogeneity

The low-grade chondrosarcoma pattern consists of cartilage cells that permeate marrow spaces and completely replace the marrow fat. The cartilage cells directly abut and surround the lamellar bone in the chondrosarcoma pattern.

### **Treatment**

It requires surgical excision for cure

Current chemotherapy and radiation have no significant role

Grading systems are not standardized.

Low grade tumours amenable to limb sparing procedures.

Radical radiotherapy may be used to control inoperable

### **EWINGS SARCOMA**

Common site is Femur [20%]

More common in males, less than 20 years

### **Clinical**

Pain, tenderness, fever

Anemia, leukocytosis, ESR

May mimic osteomyelitis



## **X Ray**

Lytic,

Moth eaten or permeative

Laminated periosteal reaction

(Onion peel) or sub burst

appearance



**With Modern Chemotherapy:** Survival is 70%

### **Present treatment**

Pre-op Chemotherapy

Surgical resection when possible [otherwise radiotherapy]

Limb sparing surgery like osteosarcoma

Monitor for recurrence

### **Chemotherapy**

Doxorubicin + Vincristine + cyclophosphamide + Actinomycin D + Adriamycin . Recently: added Ifosfamide

**Lung radiotherapy** is indicated for patients with lung metastases

## Myeloma

Usually occurs in 50 -80years

Common primary bone tumor 45%

Males more commonly affected

Lymphocytes produce the same immunoglobulin. These Ig are called the paraproteins is common. IgG 55%

In some patients only part of the Ig is produced, usually the light chain and these appear as Bence-Jones proteinuria.

IgA myeloma [21%] carries poor prognosis

## Clinical

Bone pain - usually ribs and vertebral

Pathological fracture

Deposition of amyloid [15%]

Hypercalcaemia

Amyloidosis

## Investigations

General	Hemoglobin and ESR
State of renal function	Urea and electrolytes
Bone destruction	Blood Calcium is high
Presence of bone fractures	X ray, Alkaline Phosphatase
Degree of immune	Plasma Ig [Electroporesis]
Degree of bone marrow	blood counts, Plasmacytes
Degree of haemostasis	bleeding time, coagulation screen
Disease activity	Serum beta2 microglobulin


## Radiography

Classic punched out lesions

Osteopenia or collapse vertebra

Skeletal survey: Skull, Chest, Pelvis

Spine: vertebral fracture



Sheets of cells

Eccentric nucleus

Cartwheel appearance

### **Treatment**

#### **1. Melphalan**

#### **2. Prednisone**

Combination chemotherapy shown to prolong overall survival

#### **3. Radiation is very effective for localized lesions.**

#### **4. Surgical intervention: Prophylactic fixation in impending**

Spine with instability neurologic: Decompression

### **Monitoring**

Total count and platelets

ESR

Serial serum protein electrophoresis or test for quantitative Ig

Serum B microglobulin

X ray: Resolution of the skeletal disease.

### **HYCALCEMIA**

Common in Myeloma

Secondaries in the bone

### **Clinical**

Confusion. Lethargy, Coma

Heart stops in systole

### **Treatment**

Rehydrate

Prednisolone 30-40mg daily

Frusemide

Role of Pamidronate IV [Biphosphonates]

The overall prognosis for patients with myeloma patients tend to die within 3 years

Chemotherapy improves the median survival time to 3 years in the 50% to 60% who respond to treatment.

### **Solitary plasmacytoma**

Lab investigations are normal

Younger than multiple myeloma

Solitary bone lesion

When Spine: Paraplegia is more common than myeloma

70% of solitary, will develop multiple myeloma and will usually die within 5 years

Radiation or en-bloc excision

Need close long follow up.